The Zhitong Finance App learned that Goldman Sachs released a research report stating that it gave a “buy” rating to Pharmaceutical Federation (02268.HK), with a target price of HK$97.9, corresponding to predicting a price-earnings ratio of about 35 times for the next 12 months. The bank pointed out that the backlog of orders is strong, and commercialization visibility is improving. It continues to be optimistic about its growth prospects for many years to come. Commercial catalysts are also becoming increasingly clear. The number of process verification (PPQ) projects has reached 21, and it is expected that the number of new drug marketing applications (BLA) submissions will rise.

The Zhitong Finance App learned that Goldman Sachs released a research report stating that it gave a “buy” rating to Pharmaceutical Federation (02268.HK), with a target price of HK$97.9, corresponding to predicting a price-earnings ratio of about 35 times for the next 12 months. The bank pointed out that the backlog of orders is strong, and commercialization visibility is improving. It continues to be optimistic about its growth prospects for many years to come. Commercial catalysts are also becoming increasingly clear. The number of process verification (PPQ) projects has reached 21, and it is expected that the number of new drug marketing applications (BLA) submissions will rise.